Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Rating Increased to Buy at Societe Generale

Societe Generale upgraded shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMSFree Report) from a hold rating to a buy rating in a research note released on Friday morning, MarketBeat reports.

FMS has been the subject of several other research reports. StockNews.com lowered Fresenius Medical Care AG & Co. KGaA from a strong-buy rating to a hold rating in a report on Friday, November 3rd. Morgan Stanley upped their target price on Fresenius Medical Care AG & Co. KGaA to €40.50 ($44.51) in a research note on Wednesday, August 16th. Citigroup initiated coverage on Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 1st. They issued a neutral rating for the company. Truist Financial cut their target price on Fresenius Medical Care AG & Co. KGaA from $28.00 to $24.00 and set a hold rating for the company in a research note on Wednesday, October 11th. Finally, UBS Group raised Fresenius Medical Care AG & Co. KGaA from a sell rating to a neutral rating in a research note on Wednesday, September 13th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has an average rating of Hold and an average price target of $25.40.

Read Our Latest Research Report on Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA Stock Down 0.6 %

Shares of NYSE FMS opened at $19.61 on Friday. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $14.82 and a 12 month high of $27.72. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $11.51 billion, a price-to-earnings ratio of 23.91 and a beta of 1.04. The business has a 50-day moving average of $19.29 and a 200-day moving average of $22.36.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Free Report) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.06). Fresenius Medical Care AG & Co. KGaA had a return on equity of 4.85% and a net margin of 2.30%. The business had revenue of $5.37 billion for the quarter, compared to analysts’ expectations of $5.42 billion. During the same period in the previous year, the firm posted $0.40 EPS. Sell-side analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.25 earnings per share for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dodge & Cox raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 20.5% during the first quarter. Dodge & Cox now owns 4,223,110 shares of the company’s stock valued at $89,783,000 after acquiring an additional 718,910 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 77.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,570,817 shares of the company’s stock valued at $25,667,000 after acquiring an additional 683,851 shares in the last quarter. Morgan Stanley raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 3.7% during the third quarter. Morgan Stanley now owns 1,041,447 shares of the company’s stock valued at $22,433,000 after acquiring an additional 36,820 shares in the last quarter. Balyasny Asset Management L.P. raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 69.5% during the first quarter. Balyasny Asset Management L.P. now owns 750,610 shares of the company’s stock valued at $15,958,000 after acquiring an additional 307,801 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 58.8% during the second quarter. Goldman Sachs Group Inc. now owns 736,847 shares of the company’s stock valued at $17,633,000 after acquiring an additional 272,886 shares in the last quarter. Institutional investors own 5.81% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

(Get Free Report)

Fresenius Medical Care AG & Co KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Articles

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.